Pricing Log in Create free account
Saturday 7 November 2026 Export AVTX’s income statement to Excel — free account

Avalo Therapeutics, Inc.

AVTX Healthcare Biotechnology

Avalo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $59,000.00, down 86.6% from fiscal 2024.

Revenue
−70.1%
EPS
+56.8%
Free cash flow
+75.7%

Quarter to June 2026, against a year earlier

6.95 0.32 +4.83%
Market cap
$355.6M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
2/9
Altman Z
−2.13
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 8.34
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 1 4 7 2 1 5 2 — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 355.56
Revenue ttm 1.25
Net income ttm (100.33)
Free cash flow ttm (68.29)
Net debt Q (400.32)
Valuation
P/E 0.00
Forward P/E (2.53) (negative: loss-making)
Price / sales 243.01 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.68
Financial health
Current ratio Q 19.31 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 13.34
Growth
Revenue growth Q −70.14% (below 0%: shrinking)
Operating income growth Q −63.17% (below 0%: shrinking)
EPS, this year +56.54% (at or above 15%: strong)
EPS, next year A +0.98%
Revenue, next year A +280.51% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +25.24% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −68.8×, against a ten-year median of 6.0×; over the ten years it ranged from −1,200× in 2019 to 364× in 2026.
P/S against its own 10 years 95.02%
10-year low 10-year high
P/B against its own 10 years 13.76%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 7 135 98 400
Receivables 0 1 — —
Inventory — — — —
Other — — — —
8 139 105 408
2023 2024 2025 Q'26
Payables 0 0 0 3
ST’ Debt — — — —
Other — 0 — —
5 7 13 21

Compound Annual Growth %

10y 5y 3y
Sales — (61.19%) (85.16%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 20.30% 27.59% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.66 Actual −0.83

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −1.67 −2.19 Miss by 0.52
Q4 FY25 −1.54 −0.37 Beat by 1.17
Q1 FY26 −1.00 −0.98 Beat by 0.02
Q2 FY26 −0.66 −0.83 Miss by 0.17
Q3 FY26 −0.63 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.98) (0.83) — — —
’25 (1.25) (1.92) (2.19) (0.75) (5.84)
’24 (141.00) (14.07) (2.83) (3.43) (20.91)
’23 (202.38) (140.48) (26.19) (10.10) (114.00)
’22 (571.66) (328.57) 80.95 (247.62) (1.05k)
’21 (914.65) (514.49) (485.91) (392.83) (2.37k)
’20 (971.82) (543.07) (485.91) (484.51) (2.46k)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 0
’24 — — 0 0 0
’23 0 1 0 1 2
’22 1 1 15 1 18
’21 0 3 1 0 5
’20 3 1 1 1 7
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) (20) — — —
’25 (9) (11) (16) (14) (51)
’24 (6) (16) (12) (15) (49)
’23 (10) (11) (7) (3) (31)
’22 (16) (12) 6 (4) (27)
’21 (18) (19) (16) (17) (71)
’20 (6) (9) (12) (14) (41)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) (20) — — —
’25 (9) (82) (16) (14) (51)
’24 (6) (16) (12) (15) (49)
’23 (10) (11) (7) (3) (31)
’22 (16) (13) 6 (4) (27)
’21 (18) (19) (16) (17) (71)
’20 (6) (9) (12) (14) (41)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 1 28 7 7 7 5 18 2 0 0 1 (28.1%) 0 — — +280.5%
Gross margin, % 100.00 97.71 53.61 108.39 95.52 72.38 80.98 33.26 182.99 100.00 64.72 0.0 pt
EBT (16) 14 (35) (16) (67) (85) (42) (32) (35) (78) (100) +18.9%
EBT margin, % (1,428.59) 49.75 (502.58) (236.88) (1,002.79) (1,566.23) (230.62) (1,638.77) (7,939.91) (132,362.71) 0.00 (130,934.1) pt
Net income (16) 12 (40) (16) (63) (84) (42) (32) (35) (78) (100) +18.9%
Per share, $
Per share, $ Revenue 371.94 4,345.80 576.10 450.03 287.51 154.23 460.48 6.93 0.10 0.00 0.00 (71.6%)
Earnings (5,344.99) 1,200.48 (3,174.71) (809.76) (2,458.13) (2,372.38) (1,054.76) (114.00) (7.94) (5.84) (4.75) (53.1%)
Cash flow (4,701.00) 1,965.44 (256.40) (1,275.62) (1,739.87) (2,025.49) (682.42) (110.48) (11.08) (3.84) (1.57) (54.6%)
Capex (11.26) (3.64) (46.26) (17.47) (2.70) (3.23) (2.42) 0.09 0.00 0.00 0.00 n/m
Free cash flow (4,712.26) 1,961.80 (302.66) (1,293.09) (1,742.58) (2,028.71) (684.85) (110.39) (11.08) (3.84) (1.57) (54.6%)
Book value 66.77 4,353.06 1,713.75 1,399.71 1,054.16 659.49 (278.44) 26.30 30.06 6.20 10.29 (23.2%)
Shares, m 0 0 0 0 0 0 0 0 4 13 23 +153.5%
Valuation, ×
Valuation, × P/E 0.00 7.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.8
P/S 0.00 2.21 16.14 34.47 26.42 31.72 2.61 3.66 61.16 195.21 243.01 37.4
P/B 38.36 2.20 5.42 11.08 7.21 7.42 0.00 0.96 0.57 2.93 0.68 7.6
EV/Sales 0.00 2.16 16.81 35.07 24.21 27.88 2.68 5.80 (37.51) 125.56 (68.78) 20.3
EV/FCF (0.39) 4.78 (31.99) (12.20) (3.99) (2.12) (1.80) (0.36) 0.95 (1.28) 0.62 (4.8)
Cash, $m
Cash, $m Operating cash flow (15) 13 (3) (19) (41) (71) (27) (31) (49) (51) (68) +15.0%
Capex 0 0 (1) 0 0 0 0 0 — — (71) n/m
Free cash flow (15) 13 (4) (19) (41) (71) (27) (31) (49) (51) (68) +15.0%
Balance, $m
Balance, $m Working capital 1 0 (4) 6 11 42 (6) 4 132 92 387 +59.9%
Net debt (3) (2) 4 (10) (16) (22) 0 (7) (135) (98) (400) +48.6%
Shareholders’ equity 0 28 21 21 25 23 (11) 7 133 83 449 +94.7%
Returns, %
Returns, % ROA (120.11) 32.00 (70.85) (30.22) (159.02) (136.12) (73.35) (116.06) (40.91) (58.58) (32.50) +61.5 pt
ROIC 0.00 34.20 (89.99) (92.94) (526.72) (4,013.58) 0.00 0.00 0.00 0.00 (118.21) 0.0 pt
ROE (247.87) 55.38 (164.27) (76.72) (278.79) (354.20) (684.77) 1,747.11 (50.06) (72.43) (36.27) +175.4 pt
People
People Employees 15 38 64 18 32 44 20 19 23 33 — +9.2%
Revenue/emp, $m 0.08 0.73 0.11 0.38 0.21 0.12 0.90 0.10 0.02 0.00 — (34.2%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2024 · fundamentals updated 26 Oct 2026

Avalo Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LYEL Lyell Immunopharma, Inc. $367.6M — (loss-making) — (loss-making) −80.00% (below 0%: shrinking) n/m −21.82% (below 0%: shrinking) 100.00% (1,609,833.33%) Compare
CCCC C4 Therapeutics, Inc. $362.9M — (loss-making) — (loss-making) −24.59% (below 0%: shrinking) n/m +17.88% (above 0%: growing) 100.00% (290.46%) Compare
ZURA Zura Bio Limited $358.3M — (loss-making) — — n/m −26.22% (below 0%: shrinking) — 0.00% Compare
TRXB TRex Bio Inc. $356.5M — — — — — — — Compare
AVTX Avalo Therapeutics, Inc. $355.6M — (loss-making) — (loss-making) −70.14% (below 0%: shrinking) n/m +75.70% (above 0%: growing) 55.73% 0.00%
RZLT Rezolute, Inc. $352.1M — (loss-making) — — n/m +40.23% (above 0%: growing) 0.00% 0.00% Compare
CTNM Contineum Therapeutics, Inc. $345.9M — (loss-making) — — n/m +10.04% (above 0%: growing) 100.00% 0.00% Compare
MPLT MapLight Therapeutics, Inc. $345.7M — (loss-making) — — n/m −31.91% (below 0%: shrinking) — 0.00% Compare
AGMB AgomAb Therapeutics NV $343.3M — — — — — — — Compare
Median of peers $354.3M — — — — −5.89% 100.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 10 April 2026

Ownership

Directors and executive officers, together 4.46%
RA Capital Management, L.P., 9.99%
OrbiMed Advisors LLC, 9.99%
BVF Partners, L.P., 9.99%
FMR LLC 8.68%
Logos Global Management LP 5.24%
Nantahala Capital Management LLC 5.04%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Avalo Therapeutics, Inc. (AVTX) Latest News

5 Nov

Impact 3 · · GlobeNewswire

22 Oct

Impact 3 · · MT Newswires

23 Sep

Impact 4 ·

11 Aug

Impact 3 ·

6 Aug

Impact 3 ·

16 Jun

Impact 4 ·

13 May

Impact 3 · · GlobeNewswire

6 May

Impact 4 · · Investor's Business Daily
Impact 4 · · biopharmadive.com

5 May

Impact 5 · · GlobeNewswire
Impact 5 · · GlobeNewswire
Impact 4 · · GlobeNewswire

28 Apr

Impact 3 · · GlobeNewswire

6 Apr

Impact 3 · · Simply Wall St.

3 Apr

Impact 4 · · Zacks

23 Mar

Impact 4 · · GlobeNewswire

12 Mar

Impact 4 · · MarketBeat

5 Mar

Impact 4 · · MarketBeat

25 Feb

Impact 4 · · MarketBeat

11 Feb

Impact 4 · · MarketBeat

6 Nov

Impact 3 · · GlobeNewswire

29 Oct

Impact 4 · · Insider Monkey
Impact 4 · · GlobeNewswire

28 Oct

Impact 4 · · Simply Wall St.

1 Oct

Impact 3 · · GlobeNewswire

22 Sep

Impact 3 ·

14 Sep

Impact 3 · · Simply Wall St.

7 Aug

Impact 3 · · GlobeNewswire

2 Jul

Impact 4 · · Insider Monkey

18 Jun

Impact 4 · · GlobeNewswire
stockrow.com/AVTX · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com